Comments
Loading...

Relmada Therapeutics

RLMDNASDAQ
Logo brought to you by Benzinga Data
$3.50
0.01000.29%
At Close: -
$3.51
0.01000.29%
After Hours: 7:41 AM EDT
15 minutes delayed
Consensus Rating1
Buy
Highest Price Target1
$53.00
Lowest Price Target1
$2.00
Consensus Price Target1
$20.80

Relmada Therapeutics (NASDAQ:RLMD) Stock, Analyst Ratings, Price Targets, Forecasts

Relmada Therapeutics Inc has a consensus price target of $20.8 based on the ratings of 7 analysts. The high is $53 issued by Goldman Sachs on March 24, 2022. The low is $2 issued by Goldman Sachs on June 5, 2024. The 3 most-recent analyst ratings were released by Jefferies, Goldman Sachs, and Mizuho on September 17, 2024, June 5, 2024, and June 15, 2023, respectively. With an average price target of $13.67 between Jefferies, Goldman Sachs, and Mizuho, there's an implied 289.36% upside for Relmada Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Jun
0
0
0
0
Sep
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.7
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Jefferies
Goldman Sachs
Mizuho
SVB Leerink
Goldman Sachs

1calculated from analyst ratings

Analyst Ratings for Relmada Therapeutics

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for Relmada Therapeutics (RLMD) stock?

A

The latest price target for Relmada Therapeutics (NASDAQ:RLMD) was reported by Jefferies on September 17, 2024. The analyst firm set a price target for $13.00 expecting RLMD to rise to within 12 months (a possible 270.37% upside). 2 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Relmada Therapeutics (RLMD)?

A

The latest analyst rating for Relmada Therapeutics (NASDAQ:RLMD) was provided by Jefferies, and Relmada Therapeutics upgraded their buy rating.

Q

When was the last upgrade for Relmada Therapeutics (RLMD)?

A

The last upgrade for Relmada Therapeutics Inc happened on September 17, 2024 when Jefferies raised their price target to $13. Jefferies previously had a hold for Relmada Therapeutics Inc.

Q

When was the last downgrade for Relmada Therapeutics (RLMD)?

A

The last downgrade for Relmada Therapeutics Inc happened on June 5, 2024 when Goldman Sachs changed their price target from $3 to $2 for Relmada Therapeutics Inc.

Q

When is the next analyst rating going to be posted or updated for Relmada Therapeutics (RLMD)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Relmada Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Relmada Therapeutics was filed on September 17, 2024 so you should expect the next rating to be made available sometime around September 17, 2025.

Q

Is the Analyst Rating Relmada Therapeutics (RLMD) correct?

A

While ratings are subjective and will change, the latest Relmada Therapeutics (RLMD) rating was a upgraded with a price target of $3.50 to $13.00. The current price Relmada Therapeutics (RLMD) is trading at is $3.51, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch